D.E. Shaw & Co
APGE

D.E. Shaw & Co’s Apogee Therapeutics APGE Stock Holding History

D.E. Shaw & Co’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7M Buy
246,086
+187,251
+318% +$16.9M 0.02% 998
2026
Q1 		$4.95M Sell
58,835
-4,415
-7% -$321K ﹤0.01% 2183
2025
Q4 		$4.77M Sell
63,250
-37,320
-37% -$2.35M ﹤0.01% 2345
2025
Q3 		$4M Sell
100,570
-93,958
-48% -$3.59M ﹤0.01% 2415
2025
Q2 		$8.45M Buy
194,528
+185,752
+2,117% +$7.07M 0.01% 1626
2025
Q1 		$328K Sell
8,776
-1,037
-11% -$40.1K ﹤0.01% 3729
2024
Q4 		$445K Sell
9,813
-39,849
-80% -$2.03M ﹤0.01% 3689
2024
Q3 		$2.92M Sell
49,662
-2,364
-5% -$113K ﹤0.01% 2402
2024
Q2 		$2.05M Buy
+52,026
New +$2.53M ﹤0.01% 2638

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

D.E. Shaw & Co's APGE Position: Q2 2026 in Review

D.E. Shaw & Co increased its Apogee Therapeutics (APGE) stake by 318% in Q2 2026, buying an estimated $16.9M and bringing the position to 246,086 shares worth $32.7M. The position accounts for 0.02% of the portfolio, ranked #998.

D.E. Shaw & Co first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • D.E. Shaw & Co held 246,086 shares of Apogee Therapeutics worth $32.7M as of Q2 2026.
  • D.E. Shaw & Co bought 187,251 Apogee Therapeutics shares in Q2 2026, an estimated $16.9M.
  • Apogee Therapeutics made up 0.02% of D.E. Shaw & Co's portfolio in Q2 2026, its #998 holding.
  • D.E. Shaw & Co first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.